Impact of prophylactic intracameral moxifloxacin on post-cataract surgery endophthalmitis: data from a tertiary eye care facility in rural India
Purpose To study the impact of prophylactic intracameral (IC) moxifloxacin on the incidence, clinical profile and outcomes in eyes developing post-cataract surgery endophthalmitis (PCE). Methods This was a single-centre, retrospective, comparative, observational study in which all eyes with PCE between June 2013 and May 2014 without IC moxifloxacin prophylaxis (group A) and June 2015–May 2016 with IC moxifloxacin prophylaxis (group B) were analysed. Results A total of 101,815 cataract surgeries were performed in group A and 112,967 in group B. PCE was diagnosed in 179 eyes (0.18%) in group A and 92 eyes (0.08%) in group B (p < 0.001). Greater reduction in risk of PCE was seen in subsidised patients compared to private. The presenting and final visual acuity was significantly better in group B (p < 0.05). Conclusions Prophylactic IC moxifloxacin reduced the incidence of PCE with maximum benefit being observed for the subsidised patients and also helped achieve a significantly better visual acuity following the resolution of endophthalmitis..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
International ophthalmology - 41(2021), 8 vom: 05. Apr., Seite 2729-2736 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shenoy, Pratik [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2021 |
|---|
| doi: |
10.1007/s10792-021-01830-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2126721957 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2126721957 | ||
| 003 | DE-627 | ||
| 005 | 20230505120823.0 | ||
| 007 | tu | ||
| 008 | 230505s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10792-021-01830-0 |2 doi | |
| 035 | |a (DE-627)OLC2126721957 | ||
| 035 | |a (DE-He213)s10792-021-01830-0-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00$jMedizin: Allgemeines |2 bkl | ||
| 100 | 1 | |a Shenoy, Pratik |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of prophylactic intracameral moxifloxacin on post-cataract surgery endophthalmitis: data from a tertiary eye care facility in rural India |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2021 | ||
| 520 | |a Purpose To study the impact of prophylactic intracameral (IC) moxifloxacin on the incidence, clinical profile and outcomes in eyes developing post-cataract surgery endophthalmitis (PCE). Methods This was a single-centre, retrospective, comparative, observational study in which all eyes with PCE between June 2013 and May 2014 without IC moxifloxacin prophylaxis (group A) and June 2015–May 2016 with IC moxifloxacin prophylaxis (group B) were analysed. Results A total of 101,815 cataract surgeries were performed in group A and 112,967 in group B. PCE was diagnosed in 179 eyes (0.18%) in group A and 92 eyes (0.08%) in group B (p < 0.001). Greater reduction in risk of PCE was seen in subsidised patients compared to private. The presenting and final visual acuity was significantly better in group B (p < 0.05). Conclusions Prophylactic IC moxifloxacin reduced the incidence of PCE with maximum benefit being observed for the subsidised patients and also helped achieve a significantly better visual acuity following the resolution of endophthalmitis. | ||
| 650 | 4 | |a Endophthalmitis | |
| 650 | 4 | |a Intracameral | |
| 650 | 4 | |a Moxifloxacin | |
| 650 | 4 | |a Cataract | |
| 650 | 4 | |a Vitrectomy | |
| 700 | 1 | |a Goh, Eunice Jin Hui |4 aut | |
| 700 | 1 | |a Kashikar, Rashmi |4 aut | |
| 700 | 1 | |a Kohli, Gaurav Mohan |4 aut | |
| 700 | 1 | |a Sachdeva, Mani |4 aut | |
| 700 | 1 | |a Naman, Vipul |4 aut | |
| 700 | 1 | |a Sood, Devindra |4 aut | |
| 700 | 1 | |a Bhatia, Priyavrat |4 aut | |
| 700 | 1 | |a Sen, Pradhnya |4 aut | |
| 700 | 1 | |a Agrawal, Rupesh |4 aut | |
| 700 | 1 | |a Sen, Alok |0 (orcid)0000-0003-2374-4187 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International ophthalmology |d Springer Netherlands, 1978 |g 41(2021), 8 vom: 05. Apr., Seite 2729-2736 |w (DE-627)168656949 |w (DE-600)800087-6 |w (DE-576)016142098 |x 0165-5701 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:8 |g day:05 |g month:04 |g pages:2729-2736 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10792-021-01830-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.00$jMedizin: Allgemeines |q VZ |0 106409646 |0 (DE-625)106409646 |
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 8 |b 05 |c 04 |h 2729-2736 | ||